Battle to keep Glaxo from break-up after Witty exit

BEFORE he became a knight of the realm, Sir Andrew Witty liked to talk about Ribena. Eight years ago, at his debut press conference as boss of Glaxo Smith Kline, he mounted a passionate defence of the syrupy drink and its importance to Britain’s biggest drug maker.

A “terrific part of the company” is how Witty described Ribena, Lucozade and Glaxo’s other consumer brands. “The first thing I talked about [today] was consumer health and that wasn’t an error,” he added.


Hossam Zeitoun
Assistant Professor of Behavioural Science and Strategy